$AVXL

ANAVEX LIFE SCIENCES CORP.

CIK:0001314052|SEC Filings

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses (recovery)
General and administrative (recovery)	$ (2,032)	$ 4,500	$ 2,385	$ 10,266
Research and development (recovery)	(4,705)	9,959	4,144	30,298
Total operating expenses (recovery)	(6,737)	14,459	6,529	40,564
Operating income (loss)	6,737	(14,459)	(6,529)	(40,564)
Other income (expense)
Grant income		25		37
Research and development incentive income	34	127	94	635
Interest income, net	1,072	1,075	3,212	3,679
Foreign exchange gain (loss)	(19)	(11)	46	(337)
Total other income, net	1,087	1,216	3,352	4,014
Net income (loss) before provision for income	7,824	(13,243)	(3,177)	(36,550)
Income tax expense, current			(18)
Net income (loss) and comprehensive income (loss)	$ 7,824	$ (13,243)	$ (3,195)	$ (36,550)
Net income (loss) per share
Net Loss per share, Basic	$ 0.08	$ (0.16)	$ (0.03)	$ (0.43)
Net Loss per share, Diluted	$ 0.08	$ (0.16)	$ (0.03)	$ (0.43)
Weighted average number of shares outstanding
Basic	92,696,842	85,380,587	91,453,995	85,085,795
Diluted	92,899,536	85,380,587	91,453,995	85,085,795

Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash Flows used in Operating Activities
Net loss	$ (3,195)	$ (36,550)
Adjustments to reconcile net loss to net cash used in operations:
Share based compensation (recovery)	(15,663)	7,828
Changes in working capital balances related to operations:
Incentive and tax receivables	(186)	1,629
Prepaid expenses and deposits	(389)	483
Accounts payable	(593)	(2,887)
Accrued liabilities	(661)	(906)
Deferred grant income		(37)
Net cash used in operating activities	(20,687)	(30,440)
Cash Flows provided by Financing Activities
Issuance of common shares, net of share issuance costs	36,430
Payment for taxes related to cashless exercise of options		(2,262)
Proceeds from exercise of stock options	6	1,679
Net cash provided by financing activities	36,436	(583)
Increase (decrease) in cash and cash equivalents during the period	15,749	(31,023)
Cash and cash equivalents, beginning of period	102,577	132,187
Cash and cash equivalents, end of period	118,326	101,164
Supplemental Cash Flow Information
Cash paid for state and local franchise taxes	113	109
Cash paid for income taxes	5
Common stock issued upon cashless exercise of stock option		$ 548

Condensed Consolidated Interim Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Sep. 30, 2025
Current
Cash and cash equivalents	$ 118,326	$ 102,577
Incentive and tax receivables	995	809
Prepaid expenses and other current assets	818	429
Total Assets	120,139	103,815
Current Liabilities
Accounts payable	3,656	4,249
Accrued liabilities - Note 3	4,036	3,892
Deferred grant income - Note 4		805
Total Liabilities	7,692	8,946
92,696,842 common shares (September 30, 2025 - 86,668,521)	93	87
Additional paid-in capital	497,997	477,230
Accumulated deficit	(385,643)	(382,448)
Total Stockholders’ Equity	112,447	94,869
Total Liabilities and Stockholders’ Equity	$ 120,139	$ 103,815